Suchergebnisse - "Cervantes, A"

PubPharm (442)

41

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Vogel, A. | Martinelli, E. | ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org | +16

42

In the literature : April 2021

enthalten in: ESMO open | 2021

von Martín-Martorell, P. | Gonzalez-Barrallo, I. | Gambardella, V. | +2

43

The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies

enthalten in: ESMO open | 2021

von Cervantes, A.

44

Design and Performance Evaluation of a Fungi-Bacteria Consortium to Biodegrade Organic Matter at High Concentration on Synthetic Slaughterhouse Wastewater

enthalten in: Water, air & soil pollution | 2021

von Robles-Morales, D. | Reyes Cervantes, A. | Díaz-Godínez, R. | +3

45

Checkpoint inhibitors for gastroesophageal cancers : dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Smyth, E. | Gambardella, V. | Cervantes, A. | +1

CommentIn: Ann Oncol. 2021 Sep;32(9):1189-1190. - PMID 33957223

46

In the literature : February 2021

enthalten in: ESMO open | 2021

von Cejalvo, J. | Gambardella, V. | Fleitas, T. | +1

47

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer : A Retrospective Pooled Analysis

enthalten in: Drugs & aging | 2021

von García-Alfonso, P. | Díaz-Rubio, E. | Abad, A. | +118

48

ESMO pays tribute to Professor José Baselga

enthalten in: Immuno-oncology technology | 2021

von Peters, S. | Tabernero, J. | Cervantes, A. | +3

49

In the literature : December 2020

enthalten in: ESMO open | 2021

von Gambardella, V. | Ibarrola-Villaba, M. | Tarazona, N. | +1

50

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Bahadoer, R. | Dijkstra, E. | van Etten, B. | +118

CommentIn: Lancet Oncol. 2021 Jan;22(1):2-3. - PMID 33301739